The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.
Outcomes for COPD pharmacological trials: from lung function to biomarkers / M., Cazzola; W., Macnee; F. J., Martinez; K. F., Rabe; L. G., Franciosi; P. J., Barnes; V., Brusasco; P. S., Burge; P. M., A; B. R., Celli; P. W., Jones; D. A., Mahler; B., Make; M., Miravitlles; C. P., Page; Palange, Paolo; D., Parr; M., Pistolesi; S. I., Rennard; M. P., Rutten; R., Stockley; S. D., Sullivan; J. A., Wedzicha; E. F., Wouters; A. T., Society; E. R., Society. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 31:(2008), pp. 416-468. [10.1183/09031936.00099306]
Outcomes for COPD pharmacological trials: from lung function to biomarkers.
PALANGE, Paolo;
2008
Abstract
The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
